ClinicalTrials.gg
RecruitingNCT06638515Updated Oct 15, 2024

Effects of Walking Apnea At Low Lung Volume on Hypoalgesia

An interventional study of Walking apnea at Low Lung Volume and Walking at normal breathing in Pain, Hypoxemia and Hypercapnia, sponsored by Universidad Rey Juan Carlos. Recruiting at 1 site in Spain. Open to participants aged 18 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2024-10-15.

Sponsored by Universidad Rey Juan Carlos · Not applicable, Interventional, and Treatment

From the registry’s dates

  • Primary completion was expected by May 2025, 1 year 6 months ago, but the record still lists the study as recruiting.
Phase
Not applicable
Study type
Interventional
Enrollment
60
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Study summary

The aim of this randomized controlled study is to explore the hypoalgesic response of a 6 minutes of intermittent walking apneas training session at low lung volume in healthy subjects; also, as secondary objectives, to analyze the cardiovascular and respiratory response produced during the intervention.

02

Conditions studied

  • Pain
  • Hypoxemia
  • Hypercapnia
  • Apneas
03

In context

Pain

10,054 studies on the registry are indexed under Pain; 1,649 are open to participants now.

This study's planned enrollment of 60 is close to the median of 66 across 8,493 interventional studies indexed under Pain.

Browse Pain studies →

Lead sponsor

Universidad Rey Juan Carlos is the lead sponsor of 114 studies on the registry; 24 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Asymptomatic subjects aged between 18 and 64 years.

Exclusion criteria

Exclusion Criteria:

  • Cardiovascular, respiratory, metabolic, neurological or osteomuscular signs or pathologies.
  • History of epilepsy.
  • Pregnant
  • Pharmacological treatment.
  • Participants who present any type of pain on the day of the measurements or who have frequently suffered pain during the previous 4 weeks.
05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Investigator, Outcomes assessor)
Enrollment
60 participants (estimated)

Study arms

  • Experimental
    Walking apnea at Low Lung Volume

    Participants walk at 6 km/h (10% slope) on treadmill for 6 minutes performing series of intermitent apneas

    Other: Walking apnea at Low Lung Volume

  • Active comparator
    Walking normal breathing

    Participants walk with normal breathing at 6 km/h (10% slope) on treadmill for 6 minutes.

    Other: Walking at normal breathing

Interventions

  • OtherWalking apnea at Low Lung Volume

    Walking apnea at low Lung Volume Participants walk at 6 km/h (10% slope) on treadmill for 6 minutes. Participants in the experimental group will perform intermittent apneas at high lung volume with a density of 5 seconds, followed by a normal breath of 5 seconds until completing the 6 minutes)

  • OtherWalking at normal breathing

    Participants walk at 6 km/h (10% slope) on treadmill for 6 minutes. Participants in the control group will remain breathing normally for these 6 minutes.

06

What researchers measure

Primary outcomes

  1. Pain pressure threshold (PPT) on thumb, anterior tibial and spinous process of C7

    PPT is tested on the dorsal base of the distal phalanx of the thumb on the dominant side and on the muscle belly of the tibialis anterior on the dominant side. The region to be pressed is marked with a pen. The patient is instructed to report with the first appearance of the sensation of "discomfort". An ascending ramp of 0.5 kg/cm/s is applied, at the rhythm of a metronome. The measurement is started on the thumb, and alternated with tibia and C7 until 3 measurements of each region are obtained, enough time to give 30 seconds of rest between measurements in the same region. This protocol has demonstrated high inter-observer reliability measuring healthy subjects (ICC = 0.91).

    Time frame: before and after intervention (up 30 minutes)

Secondary outcomes

  1. Perceived Stress Scale (PSS)

    14-item questionnaire about their thoughts and feelings in the last month. The scale has a range of scores from 0 to 56. The lower the score, the more favorable for the patient's health.

    Time frame: before intervention (up 5 minutes)

  2. Pittsburg Sleep Quality Index (PSQI)

    9-item questionnaire on sleep quality in the past month The scale has a range of scores from 0 to 21. The lower the score, the more favorable for the patient's health.

    Time frame: before intervention (up 5 minutes)

  3. Global Physical Activity Questionnaire (GPAQ)

    6-item questionnaire on the level of physical activity at work, for commuting and in leisure time.

    Time frame: before intervention (up 5 minutes)

  4. Oxygen saturation

    Oxygen saturation will be measured during the procedure by finger pulse oximetry.

    Time frame: during intervention (up 6 minutes)

  5. Blood pressure

    Systolic and diastolic blood pressure will be measured before, during and immediately after the procedure using a digital wrist sphygmomanometer.

    Time frame: before and after intervention (up 10 minutes)

  6. Rate of perceived exertion (RPE)

    RPE Borg CR-10 is used to measure how hard your body works during physical activity. It runs from 0 - 10, using numbers to rate how much effort an activity takes.

    Time frame: immediately after intervention (up 10 seconds)

  7. Heart rate

    Heart rate will be measured during the procedure by finger pulse oximetry.

    Time frame: during intervention (up 6 minutes)

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Nov 2024; primary completion for May 2025, 6 months later.

Of 3,731 non-industry interventional studies with no phase under Pain, half reached primary completion within 10 months of starting (the median), counting those still running; a quarter within 4 and three quarters within 23. This study's planned 6 months is below that.

Counting every sponsor, half of 3,830 studies reached it within 10 months; a quarter within 4 and three quarters within 23.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 9, 2024
First posted
Oct 15, 2024
StartEst.
Nov 1, 2024
Primary completionEst.
May 1, 2025
CompletionEst.
May 1, 2025
Last update
Oct 15, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 15, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06638515
Responsible party
DeAsís-Fernández, Francisco (Profesor / Investigador, Universidad Rey Juan Carlos) — Principal investigator
First posted
Oct 15, 2024
Start date
Nov 1, 2024 (estimated)
Primary completion
May 1, 2025 (estimated)
Completion
May 1, 2025 (estimated)
Last update
Oct 15, 2024

Study contacts

Francisco de Asís Fernandez
Contact
fasis.fernandez@urjc.es
(0034)667000218

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion